Arab Finance: October Pharma (OCPH) reported a net profit after tax of EGP 82.746 million during the first half (H1) of 2024, 1.25% up from EGP 81.722 million in the same half a year earlier, according to financial statements filed to the Egyptian Exchange (EGX) on August 12th.
Net sales surged to EGP 559.833 million in H1 2024, from EGP 441.226 million in H1 2023.
October Pharma is an Egypt-based company engaged in the production of human pharmaceutical preparations.
The company’s major shareholders include the Arab Company for Drug Industries and Medical Appliances as well as the Saudi-Egyptian Industrial Investment Company.